Theravance Biopharma, Inc. Cost of Goods Sold (Deprecated 2018-01-31)
Theravance Biopharma, Inc. (TBPH) reported Cost of Goods Sold (Deprecated 2018-01-31) of $6.03 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2018-02-28
- Theravance Biopharma, Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $3.12M, a 171.90% increase year-over-year.
- Theravance Biopharma, Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $985.00K, a 196.69% increase year-over-year.
- Theravance Biopharma, Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $1.36M, a 113.79% increase year-over-year.
- Theravance Biopharma, Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $565.00K, a 27.38% decline year-over-year.
- Theravance Biopharma, Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $6.03M, a 108.36% increase from fiscal 2016.
- Theravance Biopharma, Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $2.89M, a 37.86% decline from fiscal 2015.
- Theravance Biopharma, Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $4.66M, a 14.76% increase from fiscal 2014.
- Theravance Biopharma, Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $4.06M.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $4.10M derived: sum of 2 quarters · filed 2018-02-28 | $5.46M derived: sum of 3 quarters · filed 2018-02-28 | $6.03M 10-K · filed 2018-02-28 |
| 2017-09-30 | $985.00K 10-Q · filed 2017-11-08 | $2.35M derived: sum of 2 quarters · filed 2017-11-08 | $2.91M 10-Q · filed 2017-11-08 | $4.06M derived: sum of 4 quarters · filed 2018-02-28 |
| 2017-06-30 | $1.36M 10-Q · filed 2017-08-09 | $1.93M 10-Q · filed 2017-08-09 | $3.08M derived: sum of 3 quarters · filed 2018-02-28 | $3.41M derived: sum of 4 quarters · filed 2018-02-28 |
| 2017-03-31 | $565.00K 10-Q · filed 2017-05-10 | $1.71M derived: sum of 2 quarters · filed 2018-02-28 | $2.04M derived: sum of 3 quarters · filed 2018-02-28 | $2.68M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $1.48M derived: sum of 2 quarters · filed 2018-02-28 | $2.12M derived: sum of 3 quarters · filed 2018-02-28 | $2.89M 10-K · filed 2018-02-28 |
| 2016-09-30 | $332.00K 10-Q · filed 2017-11-08 | $970.00K derived: sum of 2 quarters · filed 2017-11-08 | $1.75M 10-Q · filed 2017-11-08 | $4.95M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $638.00K 10-Q · filed 2017-08-09 | $1.42M 10-Q · filed 2017-08-09 | $4.62M derived: sum of 3 quarters · filed 2018-02-28 | $5.20M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | $778.00K 10-Q · filed 2017-05-10 | $3.98M derived: sum of 2 quarters · filed 2018-02-28 | $4.56M derived: sum of 3 quarters · filed 2018-02-28 | $5.07M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $3.78M derived: sum of 2 quarters · filed 2018-02-28 | $4.29M derived: sum of 3 quarters · filed 2018-02-28 | $4.66M 10-K · filed 2018-02-28 |
| 2015-09-30 | $581.00K 10-Q · filed 2016-11-09 | $1.09M derived: sum of 2 quarters · filed 2016-11-09 | $1.46M 10-Q · filed 2016-11-09 | $4.68M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $505.00K 10-Q · filed 2016-08-09 | $875.00K 10-Q · filed 2016-08-09 | $4.10M derived: sum of 3 quarters · filed 2017-03-01 | $4.47M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $371.00K 10-Q · filed 2016-05-10 | $3.59M derived: sum of 2 quarters · filed 2017-03-01 | $3.96M derived: sum of 3 quarters · filed 2017-03-01 | $4.24M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $3.59M derived: sum of 2 quarters · filed 2017-03-01 | $3.87M derived: sum of 3 quarters · filed 2017-03-01 | $4.06M 10-K · filed 2017-03-01 |
| 2014-09-30 | $369.00K 10-Q · filed 2015-11-12 | $648.00K derived: sum of 2 quarters · filed 2015-11-12 | $836.00K 10-Q · filed 2015-11-12 | $836.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $279.00K 10-Q · filed 2015-08-13 | $467.00K 10-Q · filed 2015-08-13 | $467.00K derived: sum of 3 quarters · filed 2016-03-11 | $467.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $188.00K 10-Q · filed 2015-05-13 | $188.00K derived: sum of 2 quarters · filed 2016-03-11 | $188.00K derived: sum of 3 quarters · filed 2016-03-11 | $188.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $0.00 derived: sum of 2 quarters · filed 2016-03-11 | $0.00 derived: sum of 3 quarters · filed 2016-03-11 | $0.00 10-K · filed 2016-03-11 |
| 2013-09-30 | $0.00 10-Q · filed 2014-11-12 | $0.00 derived: sum of 2 quarters · filed 2014-11-12 | $0.00 10-Q · filed 2014-11-12 | |
| 2013-06-30 | $0.00 10-Q · filed 2014-08-14 | $0.00 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | $0.00 10-Q · filed 2014-06-24 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |